Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKD3 | O94806 | 3/20 | 1.00 |
| ▸ | PRKCG | P05129 | 3/20 | 1.00 |
| ▸ | PRKCB | P05771 | 3/20 | 1.00 |
| ▸ | PRKCA | P17252 | 3/20 | 1.00 |
| ▸ | PRKCH | P24723 | 3/20 | 1.00 |
| ▸ | PRKCI | P41743 | 3/20 | 1.00 |
| ▸ | PRKCE | Q02156 | 3/20 | 1.00 |
| ▸ | PRKCQ | Q04759 | 3/20 | 1.00 |
| ▸ | PRKCZ | Q05513 | 3/20 | 1.00 |
| ▸ | PRKCD | Q05655 | 3/20 | 1.00 |
| ▸ | PRKD1 | Q15139 | 3/20 | 1.00 |
| ▸ | VEGFA | P15692 | 2/20 | 0.89 |
| ▸ | PGF | P49763 | 2/20 | 0.89 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.89 |
| ▸ | FLT1 | P17948 | 1/20 | 0.81 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.76 |
| ▸ | MMP2 | P08253 | 4/20 | 0.75 |
| ▸ | MMP9 | P14780 | 4/20 | 0.75 |
| ▸ | SNCA | P37840 | 3/20 | 0.73 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cinnamtannin B1 SCHEMBL13284073 | 1.00 | PRKD3 (1.00) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| Cinnamtannin B1 SCHEMBL94430 | 1.00 | PRKD3 (1.00) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL16063172 | 1.00 | PRKD3 (1.00) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| Cinnamtannin B1 SCHEMBL14595057 | 1.00 | PRKD3 (1.00) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| Cinnamtannin B1 SCHEMBL20801024 | 1.00 | PRKD3 (1.00) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| Cinnamtannin D1 SCHEMBL20789227 | 1.00 | PRKD3 (1.00) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| Cinnamtannin B1 SCHEMBL20814412 | 1.00 | PRKD3 (1.00) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| Cinnamtannin B1 SCHEMBL20814634 | 1.00 | PRKD3 (1.00) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| Cinnamtannin B1 SCHEMBL20801029 | 1.00 | PRKD3 (1.00) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| Cinnamtannin B1 SCHEMBL29376280 | 1.00 | PRKD3 (1.00) | PRKD3PRKCGPRKCBPRKCAPRKCH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4581046-A2 | COMPOSITION FOR PATTERN RECOGNITION BASED TARGETING AND ACTIVATING AN INNATE IMMUNE RESPONSE | PHYTO42 (US) | 2025-07-09 | — | — | EP | claimed |
| WO-2024049790-A2 | COMPOSITION FOR PATTERN RECOGNITION BASED TARGETING AND ACTIVATING AN INNATE IMMUNE RESPONSE | Phyto42 (US) | 2024-03-07 | — | — | WO | claimed |
| US-20240066097-A1 | COMPOSITION FOR PATTERN RECOGNITION BASED TARGETING AND ACTIVATING AN INNATE IMMUNE RESPONSE | Phyto42 | 2024-02-29 | — | — | US | claimed |
| WO-2023219526-A1 | MULTITARGET ANTIVIRAL DIETARY SUPPLEMENT | PROKIN MILAN (RS) | 2023-11-16 | — | — | WO | claimed |
| US-20250073156-A1 | Topical Compositions and Methods to Promote Optimal Dermal White Adipose Tissue Composition in Vivo | GALANIN IVAN (US) | 2025-03-06 | — | — | US | disclosed |
| US-12226517-B2 | Topical compositions and methods to promote optimal dermal white adipose tissue composition in vivo | GALANIN IVAN (US) | 2025-02-18 | — | — | US | disclosed |
| WO-2024169038-A1 | MORDANT-FREE DYEING METHOD | THE HONG KONG RESEARCH INSTITUTE OF TEXTILES AND APPAREL LIMITED (CN) | 2024-08-22 | — | — | WO | disclosed |
| EP-3496844-B1 | VASCULAR CALCIFICATION AND CARDIOVASCULAR/ASSOCIATED DISEASES PREVENTION AND TREATMENT | Summit Innovation Labs LLC (US) | 2024-03-13 | — | — | EP | disclosed |
| US-20240066097-A1 | COMPOSITION FOR PATTERN RECOGNITION BASED TARGETING AND ACTIVATING AN INNATE IMMUNE RESPONSE | Phyto42 | 2024-02-29 | — | — | US | disclosed |
| EP-4291571-A2 | ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A HEAT SHOCK PROTEIN 90 BINDING DOMAIN | Seattle Children's Hospital d/b/a Seattle Children's Research Institute (US) | 2023-12-20 | — | — | EP | disclosed |
| WO-2023219526-A1 | MULTITARGET ANTIVIRAL DIETARY SUPPLEMENT | PROKIN MILAN (RS) | 2023-11-16 | — | — | WO | disclosed |
| US-20230322925-A1 | PHOSPHOLIPID ETHER (PLE) CAR T CELL TUMOR TARGETING (CTCT) AGENTS | SEATTLE CHILDREN’S HOSPITAL DBA SEATTLE CHILDREN’S RES INSTITUTE (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230255989-A1 | GLYCAN COMPOSITIONS AND USES THEREOF | DSM NUTRITIONAL PRODUCTS LLC (US) | 2023-08-17 | — | — | US | disclosed |
| US-20230172981-A1 | METHODS AND COMPOSITIONS FOR STIMULATION OF CHIMERIC ANTIGEN RECEPTOR T CELLS WITH HAPTEN LABELLED CELLS | SEATTLE CHILDRENS HOSPITAL DBA SEATTLE CHILDRENS RES INST (US) | 2023-06-08 | — | — | US | disclosed |
| US-11649288-B2 | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents | SEATTLE CHILDREN'S HOSPITAL (US) | 2023-05-16 | — | — | US | disclosed |
| WO-2022174035-A2 | ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A HEAT SHOCK PROTEIN 90 BINDING DOMAIN | SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE (US) | 2022-08-18 | — | — | WO | disclosed |
| US-11357250-B2 | Treatment and prevention of diabetes and obesity | Summit Innovation Labs LLC (US) | 2022-06-14 | — | — | US | disclosed |
| US-11344575-B2 | Vascular calcification prevention and treatment | Summit Innovation Labs, LLC (US) | 2022-05-31 | — | — | US | disclosed |
| US-20220112451-A1 | BOURBON REPLICAS PRODUCED FROM INDIVIDUAL COMPONENTS | AVA FOOD LABS, INC. | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11649288-B2 | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents | PHOSPHO1, LCAT, CD47 | PRKD3 2339/4885PRKCG 1408/4885PRKCB 2005/4885 |
| US-20230322925-A1 | PHOSPHOLIPID ETHER (PLE) CAR T CELL TUMOR TARGETING (CTCT) AGENTS | PHOSPHO1, LCAT, CD47 | PRKD3 2339/4885PRKCG 1408/4885PRKCB 2005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.